ArticleUpdates in surgery2026
Is atypical parathyroid tumor a different clinical entity than parathyroid adenoma and carcinoma? A retrospective review of a large single-center case series.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary hyperparathyroidism is primarily caused by single-gland pathology (80-85% of cases). According to the 2022 World Health Organization (WHO) guidelines (Erickson et al. in Endocr Pathol, 2022), single-gland pathologies include parathyroid adenoma, atypical parathyroid tumor and parathyroid carcinoma (Gurrado in J Clin Med 12:6297, 2023). The aim of this study is to identify differences or similarities of both pre-, intra- and post-operative characteristics between atypical parathyroid tumor and parathyroid adenoma/carcinoma, thereby establishing an appropriate follow-up protocol for atypical parathyroid tumor. We retrospectively analyzed 437 patients who underwent parathyroidectomy for primary hyperparathyroidism between 2012 and 2022 at the Thyroid Unit of ASST Santi Paolo e Carlo in Milan focusing our analysis on 352 patients with single-gland disease. Several pre-, intra-, and post-operative variables, including follow-up, were analyzed and compared using non-parametric statistical methods. Histological analysis identified 316 cases of PA (90%), 27 cases of atypical parathyroid tumor (7.7%), and 9 cases of parathyroid carcinoma (2.3%). Patients with atypical parathyroid tumor had significantly higher pre-operative PTH levels, intermediate calcium levels, falling between those of parathyroid adenoma and parathyroid carcinoma patients and larger gland diameter. No cases of disease persistence or recurrence were observed in patients with atypical parathyroid tumor after a mean follow-up of 42.8 months. APT exhibits biochemical and pathological features overlap with both PA and PC. However, the lack of recurrence or persistence suggests that APT behaves more similarly to PA than PC. The favorable evolution of APT in our case series could be a factor in favor of reducing the follow-up time for atypical tumors to a shorter period than the one recommended for carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.